Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Yi Lin,Lugui Qiu,Saad Usmani,Chng Wee Joo,Luciano Costa,Benjamin Derman,Juan Du,Hermann Einsele,Carlos Fernandez de Larrea,Roman Hajek,P Joy Ho,Efstathios Kastritis,Joaquin Martinez-Lopez,Maria-Victoria Mateos,Joseph Mikhael,Philippe Moreau,Chandramouli Nagarajan,Ajay Nooka,Michael O'Dwyer,Fredrik Schjesvold,Surbhi Sidana,Niels WCJ van de Donk,Katja Weisel,Sonja Zweegman,Noopur Raje,Paula Rodriguez Otero,Larry D Anderson,Shaji Kumar,Tom Martin
DOI: https://doi.org/10.1016/s1470-2045(24)00094-9
IF: 54.433
2024-05-31
The Lancet Oncology
Abstract:Summary Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
oncology